XML 59 R29.htm IDEA: XBRL DOCUMENT
v3.24.1.u1

SIGNIFICANT AGREEMENTS AND CONTRACTS (Tables) | 12 Months Ended
--- | ---
Dec. 31, 2023
Organization, Consolidation and Presentation of Financial Statements [Abstract] |
Schedule of Collaborative Agreement Liabilities and Revenues Disaggregated by Timing of Revenue Recognition | The following table presents a summary of the activity in the Company’s contract liabilities pertaining to the Mundipharma Collaboration Agreement, Janssen Collaboration Agreement, and Melinta License Agreement during the year ended December 31, 2023 (in thousands):
Opening balance, December 31, 2022 (As Restated) | $ | 35,139 |
Payments received in advance | 1,755 |
Payments receivable | 1,488 |
Revenue from performance obligations satisfied during reporting period | (9,042) |
Closing balance, December 31, 2023 | $ | 29,340 |
Current portion of contract liabilities | $ | 25,095 |
Long-term portion of contract liabilities | 4,245 |
Total contract liabilities, December 31, 2023 | $ | 29,340 |
The following table presents our collaboration revenue disaggregated by collaborator and timing of revenue recognition (in thousands):
| Year Ended December 31, 2023
| Mundipharma |  | Janssen |  | Melinta
Revenue from Collaboration and License Agreements: |  |  |  |  |
Point in Time: |  |  |  |  |
License of Intellectual Property - upon milestones achieved | $ | 3,252 |  |  | $ | 2,347 |  |  | $ | 17,257 |
Clinical Drug Supply | 26 |  |  | — |  |  | — |
Royalties | — |  |  | — |  |  | 168 |
Over Time: |  |  |  |  |
Research and Development Services | 12,303 |  |  | 19,011 |  |  | 2,441 |
Clinical Supply Services | 840 |  |  | 1,925 |  |  | — |
Total Revenue from Collaboration and License Agreements | $ | 16,421 |  |  | $ | 23,283 |  |  | $ | 19,866 |
| Year Ended December 31, 2022
| Mundipharma |  | Janssen |  | Melinta
|  |  | (As Restated) |  |
Revenue from Collaboration and License Agreements: |  |  |  |  |
Point in Time: |  |  |  |  |
License of Intellectual Property - upon transfer of license | $ | — |  |  | $ | — |  |  | $ | 25,885 |
License of Intellectual Property - upon milestones achieved | 3,252 |  |  | 976 |  |  | — |
Clinical Drug Supply | 484 |  |  | — |  |  | — |
Over Time: |  |  |  |  |
Research and Development Services | 9,595 |  |  | 18,814 |  |  | 811 |
Clinical Supply Services | 925 |  |  | 3,706 |  |  | — |
Total Revenue from Collaboration and License Agreements | $ | 14,256 |  |  | $ | 23,496 |  |  | $ | 26,696 |

X
- References No definition available. + Details
Name: | us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Tabular disclosure of collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations. + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 808 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479402/808-10-50-1 + Details
Name: | us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration